Sinopharm vaccine | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
May 12, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, MAY 12, 2025

Sinopharm vaccine

FILE PHOTO: A vial labelled "Sinopharm COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

Some Omicron sub-variants escaping antibodies from Sinopharm shot

A nurse holds a vial of China's Sinopharm coronavirus disease (COVID-19) vaccine at a health center in Caracas, Venezuela March 7, 2021. REUTERS/Leonardo Fernandez Viloria
Covid-19 in Bangladesh

Local production of Sinopharm vaccine uncertain

File photo
Covid-19 in Bangladesh

55 lakh more doses of Sinopharm vaccine arrive from China

Sinopharm has become the first non-Western vaccine that is approved by WHO. Photo: Reuters.
Covid-19 in Bangladesh

Govt to buy 7.5 crore doses of Sinopharm vaccine: Minister

Sinopharm has become the first non-Western vaccine that is approved by WHO. Photo: Reuters.
Covid-19 in Bangladesh

30 lakh more doses of Sinopharm vaccine to arrive tonight

Govt to buy 1.5cr Sinopharm shots at lower price
Covid-19 in Bangladesh

Govt to buy 1.5cr Sinopharm shots at lower price

Photo: UNB
Covid-19 in Bangladesh

Additional Secretary made OSD soon after disclosing price of Chinese vaccine

A nurse holds a vial of China's Sinopharm coronavirus disease (COVID-19) vaccine at a health center in Caracas, Venezuela March 7, 2021. REUTERS/Leonardo Fernandez Viloria
Covid-19 in Bangladesh

Sinopharm vaccine: Efforts underway to normalise things after price disclosure

Sinopharm has become the first non-Western vaccine that is approved by WHO. Photo: Reuters.
Covid-19 in Bangladesh

Chinese citizens get Sinopharm vaccine at DMCH

Sinopharm has become the first non-Western vaccine that is approved by WHO. Photo: Reuters.
Covid-19 in Bangladesh

Bangladesh approves proposal to buy Chinese Covid-19 vaccine at $10 per dose

Photo: Collected
Covid-19 in Bangladesh

5 lakh doses of Chinese vaccine reach Dhaka

China's State Councilor and Foreign Minister Wang Yi and UAE's Foreign Minister Abdullah Bin Zayed Al Nahyan show the Chines made Coronavirus (COVID-19) vaccine Sinopharm during their meeting in Abu Dhabi, United Arab Emirates, March 28, 2021. WAM/Handout via REUTERS
Coronavirus chronicle

New UAE plant to make Covid-19 vaccine from China's Sinopharm

A booth displaying a coronavirus vaccine candidate from China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the Covid-19 outbreak, in Beijing, China September 4, 2020. REUTERS/Tingshu Wang
Coronavirus chronicle

Sinopharm needs trial results to decide if Covid-19 shot needs booster: Executive

  • Show More
  • loading...
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net